SG11202012682PA - Methods of identifying patients likely to benefit from treatment with a telomerase inhibitor - Google Patents
Methods of identifying patients likely to benefit from treatment with a telomerase inhibitorInfo
- Publication number
- SG11202012682PA SG11202012682PA SG11202012682PA SG11202012682PA SG11202012682PA SG 11202012682P A SG11202012682P A SG 11202012682PA SG 11202012682P A SG11202012682P A SG 11202012682PA SG 11202012682P A SG11202012682P A SG 11202012682PA SG 11202012682P A SG11202012682P A SG 11202012682PA
- Authority
- SG
- Singapore
- Prior art keywords
- benefit
- treatment
- methods
- telomerase inhibitor
- identifying patients
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/10—Signal processing, e.g. from mass spectrometry [MS] or from PCR
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Databases & Information Systems (AREA)
- Primary Health Care (AREA)
- Data Mining & Analysis (AREA)
- Dermatology (AREA)
- Signal Processing (AREA)
- Evolutionary Computation (AREA)
- Software Systems (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Bioethics (AREA)
- Artificial Intelligence (AREA)
- Bioinformatics & Computational Biology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862712841P | 2018-07-31 | 2018-07-31 | |
US201862772849P | 2018-11-29 | 2018-11-29 | |
PCT/US2019/043941 WO2020028261A1 (en) | 2018-07-31 | 2019-07-29 | Methods of identifying patients likely to benefit from treatment with a telomerase inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202012682PA true SG11202012682PA (en) | 2021-02-25 |
Family
ID=69230556
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202012682PA SG11202012682PA (en) | 2018-07-31 | 2019-07-29 | Methods of identifying patients likely to benefit from treatment with a telomerase inhibitor |
Country Status (15)
Country | Link |
---|---|
US (1) | US20200063214A1 (he) |
EP (1) | EP3829651A4 (he) |
JP (2) | JP7401518B2 (he) |
KR (1) | KR20210038895A (he) |
CN (1) | CN112770783A (he) |
AU (1) | AU2019315406A1 (he) |
BR (1) | BR112021001204A2 (he) |
CA (1) | CA3104537A1 (he) |
CL (4) | CL2021000251A1 (he) |
IL (1) | IL279623A (he) |
MA (1) | MA53348A (he) |
MX (1) | MX2021001255A (he) |
SG (1) | SG11202012682PA (he) |
TW (1) | TW202021626A (he) |
WO (1) | WO2020028261A1 (he) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3065828B1 (en) | 2013-11-06 | 2019-01-09 | Mayo Foundation for Medical Education and Research | Methods and materials for treating hematological malignancies |
WO2024147949A1 (en) * | 2023-01-03 | 2024-07-11 | Geron Corporation | Methods of treating myelodysplastic syndrome and monitoring the treatment |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9200327B2 (en) * | 2012-11-30 | 2015-12-01 | Geron Corporation | Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors |
SG11201504209YA (en) * | 2012-11-30 | 2015-06-29 | Geron Corp | Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors |
DK3456333T3 (da) * | 2012-12-07 | 2020-05-18 | Geron Corp | Anvendelse af telomeraseinhibitor imetelstat til behandling af myelodysplastisk syndrom |
EP3065828B1 (en) | 2013-11-06 | 2019-01-09 | Mayo Foundation for Medical Education and Research | Methods and materials for treating hematological malignancies |
CN108138234A (zh) | 2015-04-15 | 2018-06-08 | 普罗麦迪奥股份有限公司 | 治疗骨髓增生性障碍的方法 |
-
2019
- 2019-07-29 CN CN201980058284.0A patent/CN112770783A/zh active Pending
- 2019-07-29 AU AU2019315406A patent/AU2019315406A1/en active Pending
- 2019-07-29 TW TW108126821A patent/TW202021626A/zh unknown
- 2019-07-29 US US16/525,026 patent/US20200063214A1/en active Pending
- 2019-07-29 MX MX2021001255A patent/MX2021001255A/es unknown
- 2019-07-29 EP EP19844144.6A patent/EP3829651A4/en active Pending
- 2019-07-29 SG SG11202012682PA patent/SG11202012682PA/en unknown
- 2019-07-29 CA CA3104537A patent/CA3104537A1/en active Pending
- 2019-07-29 KR KR1020217004664A patent/KR20210038895A/ko unknown
- 2019-07-29 JP JP2021504280A patent/JP7401518B2/ja active Active
- 2019-07-29 BR BR112021001204-4A patent/BR112021001204A2/pt unknown
- 2019-07-29 MA MA053348A patent/MA53348A/fr unknown
- 2019-07-29 WO PCT/US2019/043941 patent/WO2020028261A1/en active Application Filing
-
2020
- 2020-12-21 IL IL279623A patent/IL279623A/he unknown
-
2021
- 2021-01-29 CL CL2021000251A patent/CL2021000251A1/es unknown
-
2022
- 2022-02-01 CL CL2022000262A patent/CL2022000262A1/es unknown
-
2023
- 2023-09-12 JP JP2023147518A patent/JP2023164560A/ja active Pending
- 2023-10-19 CL CL2023003126A patent/CL2023003126A1/es unknown
- 2023-10-19 CL CL2023003123A patent/CL2023003123A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
US20200063214A1 (en) | 2020-02-27 |
MX2021001255A (es) | 2021-04-12 |
CA3104537A1 (en) | 2020-02-06 |
JP2021531793A (ja) | 2021-11-25 |
CL2022000262A1 (es) | 2022-10-21 |
CL2021000251A1 (es) | 2021-08-20 |
MA53348A (fr) | 2022-05-04 |
IL279623A (he) | 2021-03-01 |
BR112021001204A2 (pt) | 2021-04-27 |
KR20210038895A (ko) | 2021-04-08 |
CN112770783A (zh) | 2021-05-07 |
TW202021626A (zh) | 2020-06-16 |
EP3829651A4 (en) | 2022-05-04 |
AU2019315406A1 (en) | 2021-01-21 |
EP3829651A1 (en) | 2021-06-09 |
CL2023003123A1 (es) | 2024-04-19 |
WO2020028261A1 (en) | 2020-02-06 |
JP7401518B2 (ja) | 2023-12-19 |
CL2023003126A1 (es) | 2024-04-19 |
JP2023164560A (ja) | 2023-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUE060671T2 (hu) | Eljárás fibrotikus betegségek kezelésére | |
ZA201906817B (en) | Methods of treatment using a jak inhibitor compound | |
IL275496A (he) | מעכבי גליקולאט אוקסידאז לטיפול במחלה | |
IL279260A (he) | מעכבי kdm1a לטיפול במחלות | |
IL264048A (he) | מעכבי pde9 לטיפול במחלות היקפיות | |
GB201804514D0 (en) | Treatment of pyroptosis | |
ZA201703003B (en) | Heparan sulfate biosynthesis inhibitors for the treatment of diseases | |
SG11202006374VA (en) | Treatment of demyelinating diseases | |
IL274541A (he) | שיטה לטיפול במחלות של דרכי העיכול באמצעות טראדיפיטנט | |
IL266275A (he) | טיפול במחלות cns על ידי מריצי sgc | |
IL287904A (he) | טיפול משולב במחלת דלקת פרקים | |
IL252187A0 (he) | שימוש במעכבי pan fgfr ושיטה לזיהוי חולים עם סרטן המתאימים לטיפול עם מעכב pan fgfr | |
IL283508A (he) | שיטות טיפול במחלות עם מעכבי magl | |
IL279623A (he) | שיטה לזיהוי מטופלים עם סיכוי סביר ליהנות מטיפול במעכב טלומראז | |
GB201804515D0 (en) | Treatment of necroptosis | |
GB202015959D0 (en) | Treatment of diseases involving NAD | |
IL284791A (he) | שיטות טיפול במחלות עם מעכבי magl | |
GB201805100D0 (en) | Treatment of sarcopenic diseases | |
HUE064403T2 (hu) | A H3-ligandumok új terápiás alkalmazása | |
IL286099A (he) | שיטות לטיפול במחלה תוך שימוש ב-levoketoconazole | |
IL290983A (he) | שיטות לטיפול | |
GB201918853D0 (en) | Methods of treatment | |
GB201801249D0 (en) | Methods of treatment | |
GB201900942D0 (en) | Methods of treatment | |
GB201909438D0 (en) | Treatment of diseases |